Flu Vaccine–where is the evidence?
This is an addendum to yesterday's Infomail in which we disseminated disinformation issued by the U.S. Center for Disease Control (CDC). www.ahrp.org/cms/content/view/396/80
-
-
Theory suggests that a shortage of vitamin D triggers outbreaks of flu
The Baltimore Sun reports (below) that in a paper scheduled for publication in the journal Epidemiology and Infection, a Harvard University-led team proposes that a vitamin D deficiency caused by inadequate winter sun exposure may predispose people to infection.
-
Dangerous Deception: Hiding the Evidence of Adverse Drug Effects_NEJM
FDA's slip-shod approval of defective, harmful drugs, accompanied by rubber stampped endorsements by compromised FDA advisory committees may be reaching a boiling point.
-
Psychiatrist Challenges Ethics of Yale Drug Experiment
The ethics of this radical drug experiment is being challenged by Dr. Jerald Block, a forthright psychiatrist and experienced system's analyst. His critical appraisal, published in the Bioethics Forum, Hastings Center Report.
-
Article
FDA response to AHRP procedural questions From: Cerny, Igor Sent: Wednesday, January 07, 2004 11:52 AM To: Cc: Patel, Anuja; Laughren, Thomas P Subject: RE: FDA Advisory Committee Meeting: Procedural Concerns Follow Up Flag: Follow up Flag Status: Flagged Dear Ms. Sharav: Thank you for your email of December 1,…
-
Infomail Archive, 2005
Infomail 2005 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Subscribe to the AHRP infomail list Dec 16: Drugs, Devices & Doctors – NYT Paul Krugman Dec 11: Scientific Fraud & Corruption on Both sides of Atlantic: Merck / Proctor & Gamble Dec 11: Gov Accountability…
-
Pfizer Statements RE: Bextra, Celebrex, Neurontin Shown to be Lies
Pfizer Statements RE: Bextra, Celebrex, Neurontin Shown to be Lies Fri, 08 Apr 2005 The New York Times reports that “as recently as Tuesday [Pfizer] assured Wall Street that sales of Celebrex and Bextra would soon rebound. It was the latest in a string of announcements by the company regarding…
-
Tamiflu Cited in 2 Teen Deaths – Global Plan for Influenza Action – Lancet
Tamiflu Cited in 2 Teen Deaths – Global Plan for Influenza Action – Lancet Monday, November 14, 2005 Japanese newspapers report that two teenage boys – one 14 the other 17 – died after taking one dose of the antiviral drug, Tamiflu, the drug being stockpiled in the event that…
-
Debate Over Antidepressants: FDA role in suppressing damaging data – WSJ
WSJ: Debate Over Antidepressants: FDA role in suppressing damaging data Tue, 25 May 2004 How were drug manufacturers able to conceal vital evidence of harmful antidepressant drug effects? The answer is becoming clearer by the day: federal regulators and the psychiatrists who tested these drugs in clinical trials are invested…
-
Worldwide Drug Industry Ailing – PhaRMA Giants Reeling Blockbuster Drugs Found Hazardous
Worldwide Drug Industry Ailing – PhaRMA Giants Reeling Blockbuster Drugs Found Hazardous Sat, 18 Dec 2004 Daily headlines provide confirmatory evidence supporting what critics of the drug industry have been say:ing for years. First, as The New York Times notes in one of its 4 articles about the latest “unexpected”…
-
2,610 Infants died of preventable hospital-acquired infections – Chicago Tribune
July 26, 2002 2,610 Infants died of preventable hospital-acquired infections – Chicago Tribune FYI President Bush would limit health care liability http://www.nytimes.com/2002/07/26/politics/26BUSH.html . Clearly neither he nor his advisers have considered The Chicago Tribune’s investigative series, Unhealthy Hospitals (excerpt below). This Tribune series should be required reading for members of the various research…
-
FDA reviews depression drugs–Intense or Cautious? WashPost/ NYT/ Herald
FDA reviews depression drugs–Intense or Cautious? WashPost/ NYT/ Herald Wed, 29 Oct 2003 The Washington Post correctly reports: “The association between antidepressants, particularly the selective serotonin reuptake inhibitors (SSRIs), and suicide has been controversial since the first SSRI, Prozac, came on the market in the late 1980s.” But stakeholders in…